{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.48","upperLimit":"0.96","value":"0.55"},{"groupId":"OG001","lowerLimit":"1.01","upperLimit":"1.25","value":"1.12"},{"groupId":"OG002","lowerLimit":"0.64","upperLimit":"0.87","value":"0.86"},{"groupId":"OG003","lowerLimit":"0.88","upperLimit":"1.34","value":"1.10"},{"groupId":"OG004","lowerLimit":"0.36","upperLimit":"0.97","value":"0.63"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"41"}],"units":"Participants"}],"title":"Baseline CD8/CD4 T cell ratio"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.39","upperLimit":"0.88","value":"0.64"},{"groupId":"OG001","lowerLimit":"0.88","upperLimit":"1.26","value":"1.11"},{"comment":"There was only one sample.","groupId":"OG002","lowerLimit":"NA","upperLimit":"NA","value":"0.29"},{"groupId":"OG003","lowerLimit":"0.54","upperLimit":"1.41","value":"0.99"},{"groupId":"OG004","lowerLimit":"0.33","upperLimit":"0.95","value":"0.58"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"41"}],"units":"Participants"}],"title":"Post treatment CD8/CD4 T cell ratio"}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"41"}],"units":"Participants"}],"description":"Blood samples were collected via venipuncture and immunophenotyping of PBMCs were performed by multiparameter flow cytometry for CD8/CD4 T cell ratio.","dispersionType":"Inter-Quartile Range","groups":[{"description":"Phase I Dose Level (DL) 1 Topotecan 1mg/m\\^2 intravenous (IV) (days 1-5); VX970 (M6620) 140mg/m\\^2 IV on day 5","id":"OG000","title":"Phase I DL1 Topotecan 1mg/m^2 Intravenous (IV) (Days 1-5); VX970 (M6620) 140mg/m^2 IV on Day 5"},{"description":"Phase I Dose Level (DL) 2 Topotecan 1mg/m\\^2 intravenous (IV) (days 1-5); VX970 (M6620) 140mg/m\\^2 IV on day 2, 5","id":"OG001","title":"Phase I DL 2 Topotecan 1mg/m^2 Intravenous (IV) (Days 1-5); VX970 (M6620) 140mg/m^2 IV on Day 2, 5"},{"description":"Phase I Dose Level (DL) 3 Topotecan 1.25mg/m\\^2 intravenous (IV) (days 1-5); VX970 (M6620) 140mg/m\\^2 IV on day 2, 5","id":"OG002","title":"Phase I DL3 Topotecan 1.25mg/m^2 Intravenous(IV) (Days 1-5); VX970 (M6620) 140mg/m^2 IV on Day 2, 5"},{"description":"Phase I Dose Level (DL) 4 Topotecan 1.25mg/m\\^2 intravenous (IV) (days 1-5); VX970 (M6620) 210mg/m\\^2 IV on day 2, 5","id":"OG003","title":"Phase I DL4 Topotecan 1.25mg/m^2 Intravenous(IV) (Days 1-5); VX970 (M6620) 210mg/m^2 IV on Day 2, 5"},{"description":"Phase II Dose Level (DL) 4 Topotecan 1.25mg/m\\^2 intravenous (IV) (days 1-5); VX970 (M6620) 210mg/m\\^2 IV on day 2, 5.\n\nMaximum Tolerated Dose/Recommended Phase II Dose.\n\nSmall cell lung cancer (SCLC) participants only.","id":"OG004","title":"Phase II Dose Level (DL) 4 Topotecan 1.25mg/m^2; VX970 (M6620) 210mg/m^2 Recommended Phase II Dose"}],"paramType":"MEDIAN","populationDescription":"Only one participant had a post treatment sample in phase 1 DL3.","reportingStatus":"POSTED","timeFrame":"Baseline and 3 weeks post-treatment","title":"Ratio of Peripheral Blood Mononuclear Cells (PBMCs): Cluster of Differentiation 8 (CD8)/Cluster of Differentiation 4 (CD4) T Cells at Baseline and Post-Treatment","type":"SECONDARY","unitOfMeasure":"Ratio"}